Archives
-
Tunneling Nanotubes Transport KRas in Tumors
2026-09-03
The reference study shows that tunneling nanotubes can transfer mutant KRas between tumor cells, linking intercellular oncogene exchange with reduced membrane tension and faster phospholipid flow. Its combined confocal fluorescence, optical-tweezer, and gene-interference approach provides a mechanistic framework for understanding how tumor heterogeneity may acquire a mechanically invasive phenotype.
-
BMN 673 for DNA Repair Deficiency Research
2026-09-02
BMN 673 (Talazoparib) combines subnanomolar PARP1/2 inhibition with strong PARP-DNA complex trapping, making it a precise tool for testing DNA repair vulnerabilities. This workflow connects spliceosome biology, homologous recombination status, and response profiling in HCC, SCLC, and other translational cancer models.
-
DFCP1 Controls ATGL Lipolysis in Starved Cells
2026-09-02
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of lipid droplet catabolism. Rather than simply activating ATGL, DFCP1 recruits the lipase to lipid droplets while limiting its dynamic exchange, thereby restraining starvation-driven lipolysis and refining models of lipid mobilization.
-
L-Phenylephrine in α1A Receptor Research
2026-09-01
L-Phenylephrine is an adrenergic α1A receptor agonist used to study α1-adrenergic receptor signaling, vasoconstriction, cardiomyocyte stress responses, and neural progenitor biology. Product evidence and a peer-reviewed mouse study support its value as a mechanistic research tool, but they do not establish a therapeutic use for sex-specific hypertension.
-
ML216: BLM Helicase Inhibition in Cancer Assays
2026-09-01
ML216 is a BLM helicase inhibitor for dissecting DNA repair dependencies, replication stress, and tumor cell sensitization to chemotherapy. This article explains how to distinguish BLM-specific activity from broader RecQ helicase effects and translate biochemical, cellular, and xenograft findings into rigorous assay decisions.
-
Human PSC Teratomas Reveal Skeletal Myogenic Lineage
2026-08-31
Pappas and colleagues show that human pluripotent stem cell-derived teratomas generate skeletal myogenic progenitors spanning developmental stages that resemble embryonic human myogenesis. Single-cell transcriptomics and surface-marker analysis identify ERBB3 and CD82 as useful candidates for prospective isolation, establishing teratomas as an accessible platform for studying and obtaining human muscle progenitors.
-
LLY-507: Selective SMYD2 Inhibitor Workflows
2026-08-31
LLY-507 combines sub-15 nM biochemical potency with strong target selectivity, making it useful for connecting SMYD2 methyltransferase activity to cancer-cell phenotypes. This guide translates the compound into practical methylation, proliferation, apoptosis, and renal-fibrosis assay workflows while emphasizing controls and interpretation limits.
-
GS967 for Cardiac Late Sodium Current Studies
2026-08-30
GS967 is a cardiac late sodium current inhibitor designed to separate pathological late Na⁺ influx from broader conduction effects. Its concentration-dependent activity supports workflows spanning in vitro cardiac electrophysiology, ventricular myocyte sodium current inhibition, and ex vivo arrhythmia prevention research.
-
LLY-507: Reading SMYD2 Biology Across Models
2026-08-29
LLY-507 is a selective SMYD2 inhibitor for dissecting methyltransferase-dependent signaling in cancer and tissue injury. This article presents a model-to-assay framework that separates biochemical potency, cellular target engagement, phenotype, and translational evidence.
-
Mtb–BMX Signaling Rewires Lysosomal Acidification
2026-08-28
The reference study identifies a host–pathogen mechanism in which M. tuberculosis Chp2/Rv1184 promotes BMX-dependent phosphorylation of ATP6V1E1, disrupting V-ATPase assembly and lysosomal acidification. The findings connect a secreted mycobacterial protein to a specific host kinase pathway and support further evaluation of BMX and lysosomal acidification as host-directed tuberculosis targets.
-
Tetracycline Workflows for Selection and Ribosome Studies
2026-08-28
Tetracycline supports more than routine antimicrobial selection: it enables controlled bacterial protein-synthesis studies, plasmid workflow quality control, and ribosomal function research. This guide connects practical reagent handling with assay-design lessons from a lung adenocarcinoma study while clearly separating validated findings from optimization recommendations.
-
Prednisolone Workflows for Glucocorticoid Research
2026-08-27
Build reproducible Prednisolone assays for glucocorticoid receptor signaling, inflammation modulation, and immunology research. A practical comparison with ERAD-engaging degradation highlights how to use this synthetic glucocorticoid as a pathway perturbagen without confusing it with a membrane-protein degrader.
-
GI 254023X: ADAM10 Inhibitor Workflows
2026-08-27
GI 254023X combines strong ADAM10 inhibition with more than 100-fold selectivity over ADAM17, enabling focused studies of sheddase activity, Notch1 signaling, and endothelial barrier failure. This practical guide translates its biochemical profile into cell-based workflows, orthogonal readouts, and troubleshooting strategies for vascular and immunological research.
-
SM-102: Practical LNP Workflow for mRNA Delivery
2026-08-26
Learn how to handle SM-102, assemble lipid nanoparticles, and build a reproducible mRNA delivery workflow around controlled formulation screens. The guide combines product-specific handling with machine-learning-informed comparison, emphasizing why N/P ratio, mixing, and analytical quality control must be interpreted together.
-
From S-Phase Signal to Translational Confidence
2026-08-26
A mechanistic and strategic guide to using EdU Imaging Kits (Cy3) to connect senescence-related cancer signatures with functional proliferation data, especially in cholangiocarcinoma research.